Approved drug combinations in lung oncology, 2000–2020
| Chemical name | Line of therapy | Phase I | Trial leading to approval | Sample size | EMA approval date | Approval trial phase | Histology | Class | Monoclonal antibody | Route of administration | Primary end-point trial leading to approval |
| Bevacizumab/paclitaxel/carboplatin | First | Willett (Phase I) [56]; Johnson (Phase II) [57] | Sandler [58] | n=878 | 23 August 2007 | III | nsNSCLC | Targeted agent | Yes | i.v. | MOS |
| Pemetrexed/cisplatin | First | Thödtmann [59] | Scagliotti [60] | n=1725 | 28 October 2011 | III | nsNSCLC | CT/CT | No | i.v. | MOS |
| Nintedanib/docetaxel | Second | Mross [61] | Reck [62] | n=1324 | 27 November 2014 | III | nsNSCLC | Targeted agent | No | Oral | PFS |
| nabPaclitaxel/carboplatin | First | Rizvi [63] | Socinski [64] | n=1052 | 2 March 2015 | III | SqNSCLC | Chemotherapy | No | i.v. | ORR |
| Docetaxel/ramucirumab | Second | Spratlin [65] | Garon [66] | n=1825 | 28 January 2016 | III | nsNSCLC | Targeted agent | Yes | i.v. | MOS |
| Gemcitabine/cisplatin/necitumumab | First | Kuenen [67] | Thatcher [68] | n=1093 | 24 February 2016 | III | SqNSCLC | Targeted agent | Yes | i.v. | MOS |
| Pembrolizumab/(nab)Paclitaxel/carboplatin | First | Gadgeel [69] | Paz-Ares [70] | n=559 | 14 March 2019 | III | SqNSCLC | ICP/CT/CT | Yes | i.v. | MOS PFS |
| Pembrolizumab/pemetrexed/platin | First | Gadgeel [69] | Gandhi [71] | n=616 | 15 March 2019 | III | nsNSCLC | ICP/CT/CT | Yes | i.v. | MOS PFS |
| Atezolizumab/carboplatin/etoposide | First | Horn [72] | Horn [72] | n=403 | 6 September 2019 | III | SCLC | ICP/CT/CT | Yes | i.v. | MOS PFS |
| Atezolizumab/nab-Paclitaxel/carboplatin | First | Liu [73] | West [74] | n=723 | 6 September 2019 | III | nsNSCLC | ICP/CT/CT | Yes | i.v. | MOS PFS |
| Atezolizumab/paclitaxel/carboplatin/bevacizumab | First | Liu [73] | Socinski [75] | n=692 | 6 September 2019 | III | nsNSCLC | ICP/CT/CT/TA | Yes | i.v. | MOS PFS |
EMA: European Medicines Agency; nsNSCLC: nonsquamous nonsmall cell lung cancer; MOS: median overall survival; CT: chemotherapy; PFS: progression free survival; SqNSCLC: squamous nonsmall cell lung cancer; ORR: objective response rate; ICP: immune checkpoint; SCLC: small cell lung cancer; TA: targeted agent